Nuvectis Pharma Statistics
Total Valuation
NVCT has a market cap or net worth of $114.70 million. The enterprise value is $96.55 million.
| Market Cap | 114.70M |
| Enterprise Value | 96.55M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, before market open.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NVCT has 17.77 million shares outstanding. The number of shares has increased by 22.90% in one year.
| Shares Outstanding | 17.77M |
| Shares Change (YoY) | +22.90% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 57.21% |
| Owned by Institutions (%) | 17.10% |
| Float | 5.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 9.48 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.75, with zero debt.
| Current Ratio | 2.75 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -144.80% and return on invested capital (ROIC) is -187.66%.
| Return on Equity (ROE) | -144.80% |
| Return on Assets (ROA) | -107.80% |
| Return on Capital (ROIC) | -187.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.41% in the last 52 weeks. The beta is 0.27, so NVCT's price volatility has been lower than the market average.
| Beta (1Y) | 0.27 |
| 52-Week Price Change | -55.41% |
| 50-Day Moving Average | 8.38 |
| 200-Day Moving Average | 10.18 |
| Relative Strength Index (RSI) | 36.57 |
| Average Volume (30 Days) | 93,920 |
Short Selling Information
The latest short interest is 822,550, so 4.63% of the outstanding shares have been sold short.
| Short Interest | 822,550 |
| Short Previous Month | 808,232 |
| Short % of Shares Out | 4.63% |
| Short % of Float | 16.08% |
| Short Ratio (days to cover) | 9.59 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.90M |
| Pretax Income | -22.26M |
| Net Income | -22.26M |
| EBITDA | -22.26M |
| EBIT | -22.26M |
| Earnings Per Share (EPS) | -$1.43 |
Balance Sheet
The company has $19.13 million in cash and no debt, giving a net cash position of $19.13 million or $1.08 per share.
| Cash & Cash Equivalents | 19.13M |
| Total Debt | n/a |
| Net Cash | 19.13M |
| Net Cash Per Share | $1.08 |
| Equity / Book Value | 12.20M |
| Book Value Per Share | 0.69 |
| Working Capital | 12.20M |
Cash Flow
| Operating Cash Flow | -15.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.95M |
| FCF Per Share | -$1.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NVCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.90% |
| Shareholder Yield | -22.90% |
| Earnings Yield | -19.24% |
| FCF Yield | -13.79% |
Analyst Forecast
The average price target for NVCT is $21.00, which is 222.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 222.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |